血友病の市場規模、シェア、動向分析レポート：タイプ別、治療タイプ別、治療法別、流通チャネル別、地域別、セグメント予測、2023年～2030年

血友病市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界の血友病市場規模は2023年から2030年にかけてCAGR 6.6%で拡大し、2030年には210億7,000万米ドルに達すると予測されています。

血友病治療のための遺伝子治療やモノクローナル抗体が承認され、パイプラインにそのような候補が複数存在することが市場成長の主な促進要因となっています。さらに、死亡率の低下により血友病患者の平均余命が延びていることも市場成長を促進する主要因です。

血友病をコントロールする新規治療法の開拓と上市が市場成長を後押ししています。例えば、2020年4月、FDAは、青少年（12歳以上の年齢層）および成人における出血エピソードを制御する治療オプションとして、遺伝子操作製品Sevenfact［凝固第VIIa因子（遺伝子組換え）-jncw］を承認しました。さらに、バイオマリンの血友病A治療薬Roctavianは欧州でのみ承認されており、CSLのHemgenix（etranacogene dezaparvovec-drib）は米国と欧州の両方で承認されています。バイオマリンのRoctavianは、前回却下された後、米国FDAで審査中であり、PDUFA期日は2023年6月30日に設定されています。

大手企業は、新製品の開発や戦略的提携に注力し、地理的プレゼンスを高めています。例えば、2022年4月、ノボ・ノルディスクA/Sはカナディアン・ブラッド・サービスと提携し、A型治療薬として市販されているエスペロクトとゾノベートの製品ラインナップを強化しました。さらに2023年2月、サノフィは血友病A治療用の血液凝固第VIII因子補充療法であるアルツビオのFDA承認を取得しました。

しかし、中国やインドなどの新興諸国では、軽症から中等症の診断が遅れていることが主な阻害要因となっています。市場にとってのもう一つの主要課題は、高コストと長期データ不足のために遺伝子治療へのアクセスに問題が生じる可能性があることです。例えば、ヘムジェニックス（2022年承認）を用いた治療費は1回あたり350万米ドルであり、世界で最も高額な治療法となっています。

血友病市場レポートハイライト

• 血友病市場では、血友病Aの有病率が高いこと、治療薬が複数存在することから、Aタイプが最大のシェアを占めています。また、遺伝子治療が承認されたことにより、予測期間中にCAGRが最も高くなると予測されています。
• 販売チャネル別では、専門薬局セグメントが2022年に最大の市場シェアを占めました。
• 治療法別では、因子補充療法が2022年に血友病市場で最大のシェアを占めました。これは、予防とオンデマンド治療の両方で使用される主要な治療法であるためです。
• 北米は2022年に血友病市場で最大の収益を上げる地域であったが、これは主要プレイヤーの存在、規制支援、患者の意識、有利な資金援助に起因しています。

目次

第1章 調査手法

第2章 市場の定義

第3章 エグゼクティブサマリー

第4章 血友病市場の変数、動向、および範囲

• 血友病市場系統の見通し
  • 親市場の見通し
• 普及と成長の見通しのマッピング
• 市場促進要因の分析
  • 新生児人口の増加
  • 政府の好ましい取り組み
  • 研究開発と新製品開発の増加
  • 予防治療の採用の増加
• 市場抑制要因分析
  • 治療薬の調達に伴う高額なコスト
• ポーターのファイブフォース分析
• PESTLE分析
• パイプライン分析

第5章 血友病市場- タイプ別セグメント分析、2018～2030年

• 世界の血友病市場：タイプの変動分析
• 血友病 A
• 血友病B
• その他

第6章 血友病市場- セグメント分析、治療タイプ別、2018～2030年

• 世界の血友病市場：治療タイプの変動分析
• 予防
• オンデマンド
• 治癒

第7章 血友病市場- セグメント分析、治療法別、2018～2030年

• 世界の血友病市場：治療変動分析
• 因子補充療法
• 遺伝子治療とモノクローナル抗体
• デスモプレシンおよびフィブリンシーラント

第8章 血友病市場- 販売チャネル別セグメント分析、2018～2030年

• 世界の血友病市場：流通チャネルの変動分析
• 病院薬局
• 専門薬局

第9章 血友病市場- 地域別セグメント分析、2018～2030年

• 血友病市場：地域別の展望
• 北米
  • 北米血友病市場推計・予測、2018年から2030年
  • 米国
  • カナダ
• 欧州
  • 欧州の血友病市場推計・予測、2018年から2030年
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋地域
  • アジア太平洋地域の血友病市場推計・予測、2018年から2030年
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ラテンアメリカの血友病市場推計・予測、2018年から2030年
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東とアフリカ
  • 中東およびアフリカの血友病市場推計・予測、2018年から2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第10章 競合情勢

• 企業の分類
• 参入企業の概要
• 財務実績
• 製品のベンチマーク
• 企業の市場での位置づけ
• 企業の市場シェア分析、2022年
• 企業ヒートマップ分析
• 戦略的取り組み
• 企業プロファイル
  • NOVO NORDISK A/S
  • TAKEDA PHARMACEUTICAL COMPANY LIMITED
  • F. HOFFMANN LA-ROCHE LTD.
  • BAYER AG
  • PFIZER, INC.
  • CSL BEHRING
  • BIOMARIN
  • OCTOPHARMA AG
  • SANOFI
  • SPARK THERAPEUTICS, INC.

List of Tables

• TABLE 1 List of Abbreviation
• TABLE 2 Global Hemophilia Market, By Region, 2018 - 2030 (USD Million)
• TABLE 3 North America Hemophilia Market, By Country, 2018 - 2030 (USD Million)
• TABLE 4 North America Hemophilia Market, By Type, 2018 - 2030 (USD Million)
• TABLE 5 North America Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
• TABLE 6 North America Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
• TABLE 7 North America Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
• TABLE 8 U.S. Hemophilia Market, By Type, 2018 - 2030 (USD Million)
• TABLE 9 U.S. Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
• TABLE 10 U.S. Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
• TABLE 11 U.S. Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
• TABLE 12 Canada Hemophilia Market, By Type, 2018 - 2030 (USD Million)
• TABLE 13 Canada Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
• TABLE 14 Canada Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
• TABLE 15 Canada Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
• TABLE 16 Europe Hemophilia Market, By Country, 2018 - 2030 (USD Million)
• TABLE 17 Europe Hemophilia Market, By Type, 2018 - 2030 (USD Million)
• TABLE 18 Europe Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
• TABLE 19 Europe Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
• TABLE 20 Europe Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
• TABLE 21 UK Hemophilia Market, By Type, 2018 - 2030 (USD Million)
• TABLE 22 UK Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
• TABLE 23 UK Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
• TABLE 24 UK Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
• TABLE 25 Germany Hemophilia Market, By Type, 2018 - 2030 (USD Million)
• TABLE 26 Germany Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
• TABLE 27 Germany Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
• TABLE 28 Germany Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
• TABLE 29 France Hemophilia Market, By Type, 2018 - 2030 (USD Million)
• TABLE 30 France Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
• TABLE 31 France Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
• TABLE 32 France Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
• TABLE 33 Italy Hemophilia Market, By Type, 2018 - 2030 (USD Million)
• TABLE 34 Italy Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
• TABLE 35 Italy Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
• TABLE 36 Italy Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
• TABLE 37 Spain Hemophilia Market, By Type, 2018 - 2030 (USD Million)
• TABLE 38 Spain Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
• TABLE 39 Spain Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
• TABLE 40 Spain Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
• TABLE 41 Denmark Hemophilia Market, By Type, 2018 - 2030 (USD Million)
• TABLE 42 Denmark Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
• TABLE 43 Denmark Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
• TABLE 44 Denmark Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
• TABLE 45 Sweden Hemophilia Market, By Type, 2018 - 2030 (USD Million)
• TABLE 46 Sweden Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
• TABLE 47 Sweden Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
• TABLE 48 Sweden Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
• TABLE 49 Norway Hemophilia Market, By Type, 2018 - 2030 (USD Million)
• TABLE 50 Norway Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
• TABLE 51 Norway Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
• TABLE 52 Norway Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
• TABLE 53 Asia Pacific Hemophilia Market, By Country, 2018 - 2030 (USD Million)
• TABLE 54 Asia Pacific Hemophilia Market, By Type, 2018 - 2030 (USD Million)
• TABLE 55 Asia Pacific Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
• TABLE 56 Asia Pacific Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
• TABLE 57 Asia Pacific Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
• TABLE 58 Japan Hemophilia Market, By Type, 2018 - 2030 (USD Million)
• TABLE 59 Japan Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
• TABLE 60 Japan Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
• TABLE 61 Japan Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
• TABLE 62 China Hemophilia Market, By Type, 2018 - 2030 (USD Million)
• TABLE 63 China Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
• TABLE 64 China Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
• TABLE 65 China Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
• TABLE 66 India Hemophilia Market, By Type, 2018 - 2030 (USD Million)
• TABLE 67 India Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
• TABLE 68 India Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
• TABLE 69 India Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
• TABLE 70 South Korea Hemophilia Market, By Type, 2018 - 2030 (USD Million)
• TABLE 71 South Korea Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
• TABLE 72 South Korea Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
• TABLE 73 South Korea Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
• TABLE 74 Australia Hemophilia Market, By Type, 2018 - 2030 (USD Million)
• TABLE 75 Australia Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
• TABLE 76 Australia Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
• TABLE 77 Australia Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
• TABLE 78 Thailand Hemophilia Market, By Type, 2018 - 2030 (USD Million)
• TABLE 79 Thailand Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
• TABLE 80 Thailand Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
• TABLE 81 Thailand Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
• TABLE 82 Latin America Hemophilia Market, By Country, 2018 - 2030 (USD Million)
• TABLE 83 Latin America Hemophilia Market, By Type, 2018 - 2030 (USD Million)
• TABLE 84 Latin America Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
• TABLE 85 Latin America Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
• TABLE 86 Latin America Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
• TABLE 87 Mexico Hemophilia Market, By Type, 2018 - 2030 (USD Million)
• TABLE 88 Mexico Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
• TABLE 89 Mexico Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
• TABLE 90 Mexico Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
• TABLE 91 Brazil Hemophilia Market, By Type, 2018 - 2030 (USD Million)
• TABLE 92 Brazil Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
• TABLE 93 Brazil Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
• TABLE 94 Brazil Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
• TABLE 95 Argentina Hemophilia Market, By Type, 2018 - 2030 (USD Million)
• TABLE 96 Argentina Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
• TABLE 97 Argentina Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
• TABLE 98 Argentina Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
• TABLE 99 MEA Hemophilia Market, By Country, 2018 - 2030 (USD Million)
• TABLE 100 MEA Hemophilia Market, By Type, 2018 - 2030 (USD Million)
• TABLE 101 MEA Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
• TABLE 102 MEA Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
• TABLE 103 MEA Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
• TABLE 104 South Africa Hemophilia Market, By Type, 2018 - 2030 (USD Million)
• TABLE 105 South Africa Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
• TABLE 106 South Africa Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
• TABLE 107 South Africa Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
• TABLE 108 Saudi Arabia Hemophilia Market, By Type, 2018 - 2030 (USD Million)
• TABLE 109 Saudi Arabia Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
• TABLE 110 Saudi Arabia Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
• TABLE 111 Saudi Arabia Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
• TABLE 112 UAE Hemophilia Market, By Type, 2018 - 2030 (USD Million)
• TABLE 113 UAE Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
• TABLE 114 UAE Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
• TABLE 115 UAE Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)
• TABLE 116 KUWAIT Hemophilia Market, By Type, 2018 - 2030 (USD Million)
• TABLE 117 KUWAIT Hemophilia Market, By Treatment Type, 2018 - 2030 (USD Million)
• TABLE 118 KUWAIT Hemophilia Market, By Therapy, 2018 - 2030 (USD Million)
• TABLE 119 KUWAIT Hemophilia Market, By Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

• FIG. 1 Market research process
• FIG. 2 Information procurement
• FIG. 3 Market summary
• FIG. 4 Market segmentation & scope
• FIG. 5 Market size and growth prospects
• FIG. 6 Global hemophilia market- Key market driver analysis
• FIG. 7 Global hemophilia market - Key market restraint analysis
• FIG. 8 Penetration & growth prospect mapping
• FIG. 9 Global hemophilia market - Porter's analysis
• FIG. 10 Global hemophilia market - PESTEL analysis
• FIG. 11 Global hemophilia market type outlook key takeaways
• FIG. 12 Global hemophilia market: Type movement analysis
• FIG. 13 Hemophilia A market estimates, 2018 - 2030 (USD Million)
• FIG. 14 Hemophilia B market estimates, 2018 - 2030 (USD Million)
• FIG. 15 Others market estimates, 2018 - 2030 (USD Million)
• FIG. 16 Global hemophilia market treatment outlook key takeaways
• FIG. 17 Global hemophilia market: Treatment Type movement analysis
• FIG. 18 On-demand market estimates, 2018 - 2030 (USD Million)
• FIG. 19 Cure market estimates, 2018 - 2030 (USD Million)
• FIG. 20 Prophylaxis market estimates, 2018 - 2030 (USD Million)
• FIG. 21 Global hemophilia market therapy outlook key takeaways
• FIG. 22 Global hemophilia market: Therapy movement analysis
• FIG. 23 Factor Replacement Therapy market estimates, 2018 - 2030 (USD Million)
• FIG. 24 Desmopressin & Fibrin Sealants market estimates, 2018 - 2030 (USD Million)
• FIG. 25 Gene Therapy & Monoclonal Antibodies market estimates, 2018 - 2030 (USD Million)
• FIG. 26 Regional marketplace: Key takeaways
• FIG. 27 Global hemophilia market: Regional movement analysis
• FIG. 28 North America hemophilia market, 2018 - 2030 (USD Million)
• FIG. 29 U.S. hemophilia market, 2018 - 2030 (USD Million)
• FIG. 30 Canada hemophilia market, 2018 - 2030 (USD Million)
• FIG. 31 Europe hemophilia market, 2018 - 2030 (USD Million)
• FIG. 32 UK hemophilia market, 2018 - 2030 (USD Million)
• FIG. 33 Germany hemophilia market, 2018 - 2030 (USD Million)
• FIG. 34 France hemophilia market, 2018 - 2030 (USD Million)
• FIG. 35 Spain hemophilia market, 2018 - 2030 (USD Million)
• FIG. 36 Italy hemophilia market, 2018 - 2030 (USD Million)
• FIG. 37 Denmark hemophilia market, 2018 - 2030 (USD Million)
• FIG. 38 Sweden hemophilia market, 2018 - 2030 (USD Million)
• FIG. 39 Norway hemophilia market, 2018 - 2030 (USD Million)
• FIG. 40 Asia Pacific hemophilia market, 2018 - 2030 (USD Million)
• FIG. 41 Japan hemophilia market, 2018 - 2030 (USD Million)
• FIG. 42 China hemophilia market, 2018 - 2030 (USD Million)
• FIG. 43 India hemophilia market, 2018 - 2030 (USD Million)
• FIG. 44 South Korea hemophilia market, 2018 - 2030 (USD Million)
• FIG. 45 Australia hemophilia market, 2018 - 2030 (USD Million)
• FIG. 46 Thailand hemophilia market, 2018 - 2030 (USD Million)
• FIG. 47 Latin America hemophilia market, 2018 - 2030 (USD Million)
• FIG. 48 Brazil hemophilia market, 2018 - 2030 (USD Million)
• FIG. 49 Mexico hemophilia market, 2018 - 2030 (USD Million)
• FIG. 50 Argentina hemophilia market, 2018 - 2030 (USD Million)
• FIG. 51 MEA hemophilia market, 2018 - 2030 (USD Million)
• FIG. 52 South Africa hemophilia market, 2018 - 2030 (USD Million)
• FIG. 53 Saudi Arabia hemophilia market, 2018 - 2030 (USD Million)
• FIG. 54 UAE market, 2018 - 2030 (USD Million)
• FIG. 55 Kuwait market, 2018 - 2030 (USD Million)
• FIG. 56 Strategy framework

Hemophilia Market Growth & Trends

The global hemophilia market size is expected to reach USD 21.07 billion by 2030, expanding at a CAGR of 6.6% from 2023 to 2030, according to a new report by Grand View Research, Inc. The approval of gene therapy and monoclonal antibodies for treating hemophilia and the presence of multiple such candidates in the pipeline are major drivers for market growth. In addition, the increasing life expectancy of hemophilia patients due to reduced mortality is another key factor driving market growth.

The development and launch of novel therapies to control hemophilia are propelling the market growth. For instance, in April 2020, FDA approved the genetically engineered product Sevenfact [coagulation factor VIIa (recombinant)-jncw] as a treatment option to control bleeding episodes in adolescents (of age group 12 years and above) and adults. Furthermore, the presence of 2 gene therapy products, BioMarin's Roctavian for hemophilia A, was approved only in Europe, and CSL's Hemgenix (etranacogene dezaparvovec-drib) was approved both in the U.S., and Europe demonstrates an opportunity for expansion in other regions. BioMarin's Roctavian is under review with the U.S. FDA after its previous rejection and has a PDUFA date set for June 30, 2023.

Major players are focused on developing new products and entering into strategic collaborations for enhanced geographic presence. For instance, in April 2022, Novo Nordisk A/S partnered with Canadian Blood Services to enhance its product offering with marketed drugs Esperoct and Zonovate, publicly available for treating type A. Moreover, in February 2023, Sanofi received FDA approval for its drug Altuviiio, a factor VIII replacement therapy for treating hemophilia A.

However, a key restraining factor is the delayed diagnosis of mild to moderate disease in developing countries such as China and India. Another key challenge for the market is the possible access issues for gene therapy due to its high cost and lack of long-term data. For instance, the cost of treatment using Hemgenix (Approved in 2022) is USD 3.5 million per treatment, making it the most expensive treatment in the world.

Hemophilia Market Report Highlights

• The type A segment held the largest share of the hemophilia market owing to the higher prevalence of hemophilia A and the availability of multiple products for its treatment. This segment is also expected to grow at the highest CAGR during the forecast period owing to the approval of gene therapy
• Based on the distribution channel, the specialty pharmacies segment held the largest market share in 2022, attributable to the specialized nature of the treatment required for the condition
• By therapy factor replacement therapy held the largest share of the hemophilia market in 2022, as it is the major form of treatment used in both prophylaxis and on-demand treatment
• North America was the largest revenue-generating region in the hemophilia market in 2022, which can be attributed to the presence of key players, regulatory support, patient awareness, and favorable funding assistance

Table of Contents

Chapter 1 Research Methodology

• 1.1 Market Segmentation & Scope
  • 1.1.1 Estimates And Forecast Timeline
• 1.2 Research Methodology
• 1.3 Information Procurement
  • 1.3.1 Purchased Database
  • 1.3.2 Gvr's Internal Database
  • 1.3.3 Secondary Sources
  • 1.3.4 Primary Research
  • 1.3.5 Details Of Primary Research
• 1.4 Information Or Data Analysis
  • 1.4.1 Data Analysis Models
• 1.5 Market Formulation & Validation
• 1.6 Model Details
  • 1.6.1 Commodity Flow Analysis
    • 1.6.1.1 Approach 1: Commodity Flow Approach
    • 1.6.1.2 Approach 2: Country-Wise Market Estimation Using Bottom-Up Approach
• 1.7 Global Market: Cagr Calculation
• 1.8 Research Assumptions
• 1.9 List Of Secondary Sources
• 1.10 List Of Primary Sources
• 1.11 Objectives
  • 1.11.1 Objective 1:
  • 1.11.2 Objective 2:
• 1.12 List Of Abbreviations

Chapter 2 Market Definitions

Chapter 3 Executive Summary

• 3.1 Market Summary

Chapter 4 Hemophilia Market Variables, Trends, & Scope

• 4.1 Hemophilia Market Lineage Outlook
  • 4.1.1 Parent Market Outlook
• 4.2 Penetration And Growth Prospect Mapping
• 4.3 Market Driver Analysis
  • 4.3.1 Increasing Population Of Newborns
  • 4.3.2 Favorable Government Initiatives
  • 4.3.3 Rising R&D And New Product Development
  • 4.3.4 Rising Adoption Of Prophylaxis Treatment
• 4.4 Market Restraint Analysis
  • 4.4.1 High Cost Associated With Procuring Treatment
• 4.5 Porter's Five Forces Analysis
• 4.6 Pestle Analysis
• 4.7 Pipeline Analysis

Chapter 5 Hemophilia Market - Segment Analysis, By Type, 2018 - 2030 (USD Million)

• 5.1 Global Hemophilia Market: Type Movement Analysis
• 5.2. Hemophilia A5.2.1. Hemophilia A Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 5.3. Hemophilia B
  • 5.3.1. Hemophilia B Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 5.4. Others
  • 5.4.1 Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 6 Hemophilia Market- Segment Analysis, By Treatment Type, 2018 - 2030 (USD Million)

• 6.1 Global Hemophilia Market: Treatment Type Movement Analysis
• 6.2. Prophylaxis
  • 6.2.1. Prophylaxis Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.3. On-Demand
  • 6.3.1. On-Demand Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 6.4. Cure
  • 6.4.1. Cure Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7 Hemophilia Market - Segment Analysis, By Therapy, 2018 - 2030 (USD Million)

• 7.1 Global Hemophilia Market: Therapy Movement Analysis
• 7.2. Factor Replacement Therapy
  • 7.2.1. Factor Replacement Therapy Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.2.1.1 Plasma Derived Factor Concentrates
    • 7.2.1.1.1 Plasma Derived Factor Concentrates Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.2.1.1.2 Factor Viii Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.2.1.1.3 Factor Ix Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.2.1.2 Recombinant Factor Concentrates
    • 7.2.1.2.1 Recombinant Factor Concentrates Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.2.1.2.2 Factor Viii Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.2.1.2.3 Factor Vii Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 7.2.1.2.4 Factor Vii Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.3. Gene Therapy & Monoclonal Antibodies
  • 7.3.1. Gene Therapy & Monoclonal Antibodies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 7.4. Desmopressin & Fibrin Sealants
  • 7.4.1 Desmopressin & Fibrin Sealants Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 8 Hemophilia Market - Segment Analysis, By Distribution Channel, 2018 - 2030 (USD Million)

• 8.1 Global Hemophilia Market: Distribution Channel Movement Analysis
• 8.2. Hospital Pharmacies
  • 8.2.1. Hospital Pharmacies Market Estimates And Forecasts, 2018 - 2030 (USD Million)
• 8.3. Specialty Pharmacies
  • 8.3.1. Specialty Pharmacies Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9 Hemophilia Market: - Segment Analysis, by Region, 2018 - 2030 (USD Million)

• 9.1 Hemophilia Market: Regional Outlook
• 9.2 North America
  • 9.2.1 North America Hemophilia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.2.2 U.S.
    • 9.2.2.1 Key Country Dynamics
    • 9.2.2.2 U.S. Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
    • 9.2.2.3 Target Disease Prevalence
    • 9.2.2.4 Competitive Scenario
    • 9.2.2.5 Regulatory Framework
    • 9.2.2.6 Reimbursement Scenario
  • 9.2.3 Canada
    • 9.2.3.1 Key Country Dynamics
    • 9.2.3.2 Canada Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
    • 9.2.3.3 Target Disease Prevalence
    • 9.2.3.4 Competitive Scenario
    • 9.2.3.5 Regulatory Framework
    • 9.2.3.6 Reimbursement Scenario
• 9.3 Europe
  • 9.3.1 Europe Hemophilia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.3.2 UK
    • 9.3.2.1 Key Country Dynamics
    • 9.3.2.2 UK Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
    • 9.3.2.3 Target Disease Prevalence
    • 9.3.2.4 Competitive Scenario
    • 9.3.2.5 Regulatory Framework
    • 9.3.2.6 Reimbursement Scenario
  • 9.3.3 Germany
    • 9.3.3.1 Key Country Dynamics
    • 9.3.3.2 Germany Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
    • 9.3.3.3 Target Disease Prevalence
    • 9.3.3.4 Competitive Scenario
    • 9.3.3.5 Regulatory Framework
    • 9.3.3.6 Reimbursement Scenario
  • 9.3.4 France
    • 9.3.4.1 Key Country Dynamics
    • 9.3.4.2 France Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
    • 9.3.4.3 Target Disease Prevalence
    • 9.3.4.4 Competitive Scenario
    • 9.3.4.5 Regulatory Framework
    • 9.3.4.6 Reimbursement Scenario
  • 9.3.5 Italy
    • 9.3.5.1 Key Country Dynamics
    • 9.3.5.2 Italy Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
    • 9.3.5.3 Target Disease Prevalence
    • 9.3.5.4 Competitive Scenario
    • 9.3.5.5 Regulatory Framework
    • 9.3.5.6 Reimbursement Scenario
  • 9.3.6 Spain
    • 9.3.6.1 Key Country Dynamics
    • 9.3.6.2 Spain Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
    • 9.3.6.3 Target Disease Prevalence
    • 9.3.6.4 Competitive Scenario
    • 9.3.6.5 Regulatory Framework
    • 9.3.6.6 Reimbursement Scenario
  • 9.3.7 Denmark
    • 9.3.7.1 Key Country Dynamics
    • 9.3.7.2 Denmark Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
    • 9.3.7.3 Target Disease Prevalence
    • 9.3.7.4 Competitive Scenario
    • 9.3.7.5 Regulatory Framework
    • 9.3.7.6 Reimbursement Scenario
  • 9.3.8 Sweden
    • 9.3.8.1 Key Country Dynamics
    • 9.3.8.2 Sweden Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
    • 9.3.8.3 Target Disease Prevalence
    • 9.3.8.4 Competitive Scenario
    • 9.3.8.5 Regulatory Framework
    • 9.3.8.6 Reimbursement Scenario
  • 9.3.9 Norway
    • 9.3.9.1 Key Country Dynamics
    • 9.3.9.2 Norway Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
    • 9.3.9.3 Target Disease Prevalence
    • 9.3.9.4 Competitive Scenario
    • 9.3.9.5 Regulatory Framework
    • 9.3.9.6 Reimbursement Scenario
• 9.4 Asia Pacific
  • 9.4.1 Asia Pacific Hemophilia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.4.2 Japan
    • 9.4.2.1 Key Country Dynamics
    • 9.4.2.2 Japan Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
    • 9.4.2.3 Target Disease Prevalence
    • 9.4.2.4 Competitive Scenario
    • 9.4.2.5 Regulatory Framework
    • 9.4.2.6 Reimbursement Scenario
  • 9.4.3 China
    • 9.4.3.1 Key Country Dynamics
    • 9.4.3.2 China Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
    • 9.4.3.3 Target Disease Prevalence
    • 9.4.3.4 Competitive Scenario
    • 9.4.3.5 Regulatory Framework
    • 9.4.3.6 Reimbursement Scenario
  • 9.4.4 India
    • 9.4.4.1 Key Country Dynamics
    • 9.4.4.2 India Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
    • 9.4.4.3 Target Disease Prevalence
    • 9.4.4.4 Competitive Scenario
    • 9.4.4.5 Regulatory Framework
    • 9.4.4.6 Reimbursement Scenario
  • 9.4.5 Australia
    • 9.4.5.1 Key Country Dynamics
    • 9.4.5.2 Australia Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
    • 9.4.5.3 Target Disease Prevalence
    • 9.4.5.4 Competitive Scenario
    • 9.4.5.5 Regulatory Framework
    • 9.4.5.6 Reimbursement Scenario
  • 9.4.6 South Korea
    • 9.4.6.1 Key Country Dynamics
    • 9.4.6.2 South Korea Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
    • 9.4.6.3 Target Disease Prevalence
    • 9.4.6.4 Competitive Scenario
    • 9.4.6.5 Regulatory Framework
    • 9.4.6.6 Reimbursement Scenario
  • 9.4.7 Thailand
    • 9.4.7.1 Key Country Dynamics
    • 9.4.7.2 Thailand Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
    • 9.4.7.3 Target Disease Prevalence
    • 9.4.7.4 Competitive Scenario
    • 9.4.7.5 Regulatory Framework
    • 9.4.7.6 Reimbursement Scenario
• 9.5 Latin America
  • 9.5.1 Latin America Hemophilia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 9.5.2 Brazil
    • 9.5.2.1 Key Country Dynamics
    • 9.5.2.2 Brazil Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
    • 9.5.2.3 Target Disease Prevalence
    • 9.5.2.4 Competitive Scenario
    • 9.5.2.5 Regulatory Framework
    • 9.5.2.6 Reimbursement Scenario
  • 9.5.3 Mexico
    • 9.5.3.1 Key Country Dynamics
    • 9.5.3.2 Mexico Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
    • 9.5.3.3 Target Disease Prevalence
    • 9.5.3.4 Competitive Scenario
    • 9.5.3.5 Regulatory Framework
    • 9.5.3.6 Reimbursement Scenario
  • 9.5.4 Argentina
    • 9.5.4.1 Key Country Dynamics
    • 9.5.4.2 Argentina Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
    • 9.5.4.3 Target Disease Prevalence
    • 9.5.4.4 Competitive Scenario
    • 9.5.4.5 Regulatory Framework
    • 9.5.4.6 Reimbursement Scenario
• 9.6 Middle East and Africa
  • 9.6.1 Middle East and Africa Hemophilia Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 9.6.1.1 Target Disease Prevalence
    • 9.6.1.2 Competitive Scenario
    • 9.6.1.3 Regulatory Framework
    • 9.6.1.4 Reimbursement Scenario
  • 9.6.2 South Africa
    • 9.6.2.1 Key Country Dynamics
    • 9.6.2.2 South Africa Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
    • 9.6.2.3 Target Disease Prevalence
    • 9.6.2.4 Competitive Scenario
    • 9.6.2.5 Regulatory Framework
    • 9.6.2.6 Reimbursement Scenario
  • 9.6.3 Saudi Arabia
    • 9.6.3.1 Key Country Dynamics
    • 9.6.3.2 Saudi Arabia Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
    • 9.6.3.3 Target Disease Prevalence
    • 9.6.3.4 Competitive Scenario
    • 9.6.3.5 Regulatory Framework
    • 9.6.3.6 Reimbursement Scenario
  • 9.6.4 UAE
    • 9.6.4.1 Key Country Dynamics
    • 9.6.4.2 UAE Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
    • 9.6.4.3 Target Disease Prevalence
    • 9.6.4.4 Competitive Scenario
    • 9.6.4.5 Regulatory Framework
    • 9.6.4.6 Reimbursement Scenario
  • 9.6.5 KUWAIT
    • 9.6.5.1 Key Country Dynamics
    • 9.6.5.2 Kuwait Hemophilia Market Estimates & Forecasts And Trend Analysis, 2018 - 2030 (USD Million)
    • 9.6.5.3 Target Disease Prevalence
    • 9.6.5.4 Competitive Scenario
    • 9.6.5.5 Regulatory Framework
    • 9.6.5.6 Reimbursement Scenario

Chapter 10 Competitive Landscape

• 10.1 Company Categorization
• 10.2 Participant's Overview
• 10.3 Financial Performance
• 10.4 Product Benchmarking
• 10.5 Company Market Positioning
• 10.6 Company Market Share Analysis, 2022
• 10.7 Company Heat Map Analysis
• 10.8 Strategic Initiatives
• 10.9 Company Profiles
  • 10.9.1 NOVO NORDISK A/S
  • 10.9.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED
  • 10.9.3 F. HOFFMANN LA-ROCHE LTD.
  • 10.9.4 BAYER AG
  • 10.9.5 PFIZER, INC.
  • 10.9.6 CSL BEHRING
  • 10.9.7 BIOMARIN
  • 10.9.8 OCTOPHARMA AG
  • 10.9.9 SANOFI
  • 10.9.10 SPARK THERAPEUTICS, INC.